High prevalence of adrenal cortical adenomas in patients with cerebral meningiomas

[1]  F. J. Burgos Revilla,et al.  Tumour size in adrenal tumours: its importance in the indication of adrenalectomy and in surgical outcomes—a single-centre experience , 2022, Journal of Endocrinological Investigation.

[2]  A. Giustina,et al.  Adrenal schwannoma: why should endocrinologists be aware of this uncommon tumour? , 2022, Endocrine.

[3]  M. Hage,et al.  Estrogen and Progesterone Therapy and Meningiomas. , 2021, Endocrinology.

[4]  F. Beuschlein,et al.  Plasma steroid profiling in patients with adrenal incidentaloma. , 2021, The Journal of clinical endocrinology and metabolism.

[5]  M. Schott,et al.  DHEAS and Differential Blood Counts as Indirect Signs of Glucocorticoid Excess in Adrenal Non-Producing Adenomas , 2021, Hormone and Metabolic Research.

[6]  F. Ceccato,et al.  Frequently asked questions and answers (if any) in patients with adrenal incidentaloma , 2021, Journal of Endocrinological Investigation.

[7]  A. Moraes,et al.  Adrenal incidentaloma as a novel independent predictive factor for periodontitis , 2021, Journal of Endocrinological Investigation.

[8]  A. Formenti,et al.  Osteopathy in mild adrenal Cushing's syndrome and Cushing disease. , 2021, Best practice & research. Clinical endocrinology & metabolism.

[9]  Y. Aso,et al.  Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report. , 2020, European journal of endocrinology.

[10]  A. Grangeia,et al.  ARMC5 Primary Bilateral Macronodular Adrenal Hyperplasia Associated with a Meningioma: A Family Report , 2020, Case reports in endocrinology.

[11]  A. Scarsbrook,et al.  Adrenal Incidentaloma , 2020, Endocrine reviews.

[12]  G. Occhi,et al.  Allelic Variants of ARMC5 in Patients With Adrenal Incidentalomas and in Patients With Cushing's Syndrome Associated With Bilateral Adrenal Nodules , 2020, Frontiers in Endocrinology.

[13]  C. Stratakis,et al.  Molecular mechanisms of ARMC5 mutations in adrenal pathophysiology. , 2019, Current opinion in endocrine and metabolic research.

[14]  B. Bataille,et al.  Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment , 2019, Neuro-oncology advances.

[15]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[16]  C. James,et al.  An overview of meningiomas. , 2018, Future oncology.

[17]  Ashish K. Jha,et al.  Health Care Spending in the United States and Other High-Income Countries , 2018, JAMA.

[18]  S. Santagata,et al.  Uncovering the links between systemic hormones and oncogenic signaling in the pathogenesis of meningioma. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  M. Sanson,et al.  Progestin-associated shift of meningioma mutational landscape , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  R. Lloyd,et al.  WHO classification of tumours of endocrine organs , 2017 .

[21]  F. Faucz,et al.  Analysis of ARMC5 expression in human tissues , 2017, Molecular and Cellular Endocrinology.

[22]  A. Powlson,et al.  Low DHEAS: A Sensitive and Specific Test for the Detection of Subclinical Hypercortisolism in Adrenal Incidentalomas , 2016, The Journal of clinical endocrinology and metabolism.

[23]  F. Faucz,et al.  The ARMC5 gene shows extensive genetic variance in primary macronodular adrenocortical hyperplasia. , 2015, European journal of endocrinology.

[24]  A. Comlekçi,et al.  DHEAS for the prediction of subclinical Cushing’s syndrome: perplexing or advantageous? , 2015, Endocrine.

[25]  D. Adelson,et al.  ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. , 2014, The Journal of clinical endocrinology and metabolism.

[26]  Minghui He,et al.  Activating hotspot L205R mutation in PRKACA and adrenal Cushing’s syndrome , 2014, Science.

[27]  P. Hamet,et al.  ARMC5 mutations are a frequent cause of primary macronodular adrenal Hyperplasia. , 2014, The Journal of clinical endocrinology and metabolism.

[28]  T. Wieland,et al.  Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. , 2014, The New England journal of medicine.

[29]  M. Sibony,et al.  ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. , 2013, The New England journal of medicine.

[30]  James Hadfield,et al.  Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension , 2013, Nature Genetics.

[31]  G. Kantor,et al.  Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000-2007. , 2011, Neuro-oncology.

[32]  S. Mane,et al.  K+ Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension , 2011, Science.

[33]  J. Bertherat,et al.  Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. , 2010, The Journal of clinical endocrinology and metabolism.

[34]  Joseph Wiemels,et al.  Epidemiology and etiology of meningioma , 2010, Journal of Neuro-Oncology.

[35]  A. Hofman,et al.  Incidental findings on brain MRI in the general population. , 2007, The New England journal of medicine.

[36]  G. Scagliotti,et al.  Prevalence of adrenal incidentaloma in a contemporary computerized tomography series , 2006, Journal of endocrinological investigation.

[37]  I. Ilias,et al.  Current views on imaging of adrenal tumors. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[38]  P. Fischer,et al.  Frequency and risk factors for meningioma in clinically healthy 75‐year‐old patients , 2004, Cancer.

[39]  E. Menis,et al.  Development of a meningioma in a patient with acromegaly during octreotide treatment: Are there any causal relationships? , 2003, Journal of endocrinological investigation.

[40]  M. Lockhart,et al.  Imaging of adrenal masses. , 2002, European journal of radiology.

[41]  W. Donegan,et al.  Estrogen-receptor protein in intracranial meningiomas. , 1979, Journal of neurosurgery.

[42]  H. Cushing,et al.  MENINGIOMAS ARISING FROM THE TUBERCULUM SELLAE: WITH THE SYNDROME OF PRIMARY OPTIC ATROPHY AND BITEMPORAL FIELD DEFECTS COMBINED WITH A NORMAL SELLA TURCICA IN A MIDDLE-AGED PERSON , 1929 .

[43]  E. Kebebew.  Management of Adrenal Masses in Children and Adults , 2017 .

[44]  P. May,et al.  Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma. , 2015, The Journal of clinical endocrinology and metabolism.

[45]  P. Wen,et al.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review , 2014 .

[46]  W. Young.  Clinical practice. The incidentally discovered adrenal mass. , 2007, The New England journal of medicine.

[47]  G. Arnaldi,et al.  Adrenal incidentaloma. , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[48]  A. Buge,et al.  [Estrogen and progestin receptors in meningiomas: a study in 22 cases (author's transl)]. , 1980, Revue neurologique.

[49]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.